SYRE Q1 2025 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$54M

Net Income

-$45M

EPS (Diluted)

$-0.13

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$41M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$570M

Total Liabilities

$87M

Stockholders' Equity

$483M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$54M	-$48M	-12.1%
Net Income	-$45M	-$44M	-2.1%